Effect of raw materials on drug release from developed Ciprofloxacin tablets
DOI:
https://doi.org/10.3329/sjps.v2i2.5819Keywords:
Ciprofloxacin tablets, dissolution behavior, physicochemical properties, storage conditionsAbstract
The present study was undertaken to assess and evaluate the effect of two parameters on tablet formulationof Ciprofloxacin: a) particle size of raw material and b) storage conditions of both raw material and finished
product. The raw materials were two commercial products, coarse (RM1) and fine (RM2) and locally
produced granular form (RM3) prepared from RM2. Three tablet formulations were prepared from the raw
materials and designated as F1, F2 and F3. The formulation F1 were prepared from RM1, F2 from RM2 by
slugging and F3 from RM3 by direct compression. The raw materials and finished products were then
subjected to assessment of the different parameters at the time of production and after storage for three
month. The particle size distribution for the raw materials was found to be < 100, 100 – 250 and > 250 μm for
RM2, RM1 and RM3, respectively. The moisture uptake at 25°C and 4°C under 75% RH was found to be the
highest for the fine powder raw material (RM2), however, the developed granular form RM3 showed the least
uptake. Moreover, F2 did not attain 80% dissolution after storage of 3 month. The F1 and F3 formulation
passed the dissolution test after storage of 3 month, hence, F3 showed the highest value of dissolution (82%)
in 30 minutes. The physicochemical properties of raw materials, storage conditions, and manufacturing
techniques were found to exert a great influence over the dissolution behavior of Ciprofloxacin tablet
formulations.
Key words: Ciprofloxacin tablets; dissolution behavior; physicochemical properties; storage conditions
DOI: 10.3329/sjps.v2i2.5819
Stamford Journal of Pharmaceutical Sciences Vol.2(2) 2009: 8-15
Downloads
286
663
Downloads
How to Cite
Issue
Section
License
As a condition of publication, all authors must transfer copyright to the Department of Pharmacy. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur in the submission, and that the final version of the manuscript has been seen and approved by them.Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.